Ambition of the
Path-for-young Project
The main ambition of
Path-for-young is to set and implement a new Standard of Care (SoC) for premenopausal patients with high-risk HR+HER2-BC. Using a stratification strategy, Path-for-young will:
- predict benefit from chemotherapy for
- premenopausal patients,
- personalize adjuvant treatment choices,
prevent quality of life deterioration by avoiding long-term treatment-related effects, - improve supportive care strategies including better utilization of digital health tools, and
- integrate the participation of patients during conceptualization and implementation of the project.
Additionally, the project aims to provide the following results.
For patients and
the general population
-
- preservation and improvement of several domains of quality of life among premenopausal survivors of BC,
- improved adherence to ET,
- better understanding how to support premenopausal women with a diagnosis of early stage, higher risk breast cancer by promoting the implementation of personalized survivorship medicine and facilitating patient empowerment along the pathway of care,
- promotion of a process of co-creation and co-design of clinical trials and interventions with key stakeholders, including patient
- more accurate information about treatment pathways.
For the general
health care professionals
- access to improved clinical recommendations and therapeutic decisional tools better understanding of the benefit derived by breast cancer patients from adjuvant CT,
- better understanding of the benefit derived by breast cancer patients from adjuvant CT,
- better understanding of the patient experience, process of therapeutic choices,
- better understanding of how to support patients,
- increased awareness of personalized, predictive, proactive, participatory, and psychocognitive medicine.
For decision makers and health authorities
-
- provision of scientific evidence and multi-national HTA including robust cross-country cost-economic analysis of multiparameter assay driven treatment strategies,
- demonstration of the feasibility of implementation of a personalized non-invasive diagnostic driven strategy on a global scale,
- identification of adequate care pathways models for the delivery of optimal care for premenopausal patients with high-risk BC.
For the medical research community
- creation of a sustainable digital research infrastructure to decentralise research, facilitating pragmatic approaches, data sharing and patient engagement, including fostering equity, inclusion, and diversity in clinical trials;
- promote the understanding and implementation of large pragmatic clinical trials and de-escalation trials.
For industry/small and medium enterprises (SMEs)
Prospective development of new personalized digital patient companion promoting self-management by RESILIENCE (SME partner of the consortium). In addition, Path-for-young will foster the international use of KLINEO (second SME partner of the consortium), a tool to aid clinicians and patients screen and self-screen, respectively, for eligibility for clinical trial inclusion and foster connections with research teams, currently implemented at the French national Level. Additional SMEs will have the opportunity to benefit from the project, since it will open opportunities for ancillary exploitation of data collected, including validation of additional multiparameter gene expression assays, and building algorithms for risk stratification of long-term toxicities.
The Consortium is engaging in discussions with Veracyte, provider of the Prosigna testing used in Optima-young (see Clinical Studies Annex for details), to ensure maximal industrial valorisation of the scientific results generated by the project. If successful, this project will open new market opportunities to Prosigna and similar tests.
